DrugPatentWatch Database Preview

ALTABAX Drug Profile

« Back to Dashboard

When do Altabax patents expire, and when can generic versions of Altabax launch?

Altabax is a drug marketed by Aqua Pharms Llc and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-nine patent family members in thirty-five countries.

The generic ingredient in ALTABAX is retapamulin. Two suppliers are listed for this compound. Additional details are available on the retapamulin profile page.

Summary for ALTABAX

International Patents:	69
US Patents:	3
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	50
Clinical Trials:	5
Patent Applications:	246
DailyMed Link:	ALTABAX at DailyMed

Generic Entry Opportunity Date for ALTABAX

NDA:

022055

Dosage:

OINTMENT;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ALTABAX

Drug Class

Pleuromutilin Antibacterial

Synonyms for ALTABAX

(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxotricyclo[5.4.3.0;{1,8}]tetradecan-6-yl 2-{[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl}acetate

(3aS,4R,5S,6S,8R,9R,9aR,10R)-2-(exo-8-Methyl-8-azabicyclo[3.2.1]octan-3-ylsulfanyl)acetic acid 5-hydroxy-4,6,9,10-tetraMethyl-1-oxo-6-vinylperhydro-3a,9-propanocyclopentacycloocten-8-yl ester (RETAPAMULIN)

(3as,4r,5s,6s,8r,9r,9ar,10r)-5-Hydroxy-4,6,9,10-Tetramethyl-1-Oxo-6-Vinyldecahydro-3a,9-Propanocyclopenta[8]annulen-8-Yl {[(3-Exo)-8-Methyl-8-Azabicyclo[3.2.1]oct-3-Yl]thio}acetate

224452-66-8

345632-67-9

452R668

4MG6O8991R

AB01566905_01

AK110479

AKOS016008865

AKOS030485971

Altabax (Glaxo)

Altargo

AN-607

AS-11455

BC677692

C30H47NO4S

CR0022

CS-0618

DB01256

HY-17010

MFCD11045316

MolPort-006-167-754

MolPort-023-220-081

MP-0763

Retapamulin

Retapamulin [USAN:INN:BAN]

retpamulin

RL02708

s4056

SB 275833

SB-275833

SB275833

SCHEMBL365459

ST24025747

UNII-4MG6O8991R

ZINC100013500

ZINC103660515

ZINC3931840

US Patents and Regulatory Information for ALTABAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aqua Pharms Llc	ALTABAX	retapamulin	OINTMENT;TOPICAL	022055-001	Apr 12, 2007		RX	Yes	Yes				Y
Aqua Pharms Llc	ALTABAX	retapamulin	OINTMENT;TOPICAL	022055-001	Apr 12, 2007		RX	Yes	Yes
Aqua Pharms Llc	ALTABAX	retapamulin	OINTMENT;TOPICAL	022055-001	Apr 12, 2007		RX	Yes	Yes			Y	Y

International Patents for ALTABAX

Country	Document Number	Estimated Expiration
Hungary	S1400060
Poland	197672
Cyprus	1112062
European Patent Office	1028961
Portugal	1930330
Japan	2009040789
Norway	20091344

Supplementary Protection Certificates for ALTABAX

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2007 00052	Denmark
1028961/01	Switzerland		PRODUCT NAME: RETAPAMULIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58641 04.08.2009
C/GB07/061	United Kingdom		PRODUCT NAME: RETAPAMULIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/390/001 20070524; UK EU/1/07/390/002 20070524; UK EU/1/07/390/003 20070524; UK EU/1/07/390/004 20070524
6	Finland
372	Luxembourg		91372, EXPIRES: 20220524
C042/2007	Ireland		SPC042/2007: 20080415, EXPIRES: 20220523
C0057	France		PRODUCT NAME: RETAPAMULIN; REGISTRATION NO/DATE IN FRANCE: EU/1/07/390/001 DU 20070524; REGISTRATION NO/DATE AT EEC: EU/1/07/390/001 DU 20070524